Home 4 Reasons To Keep An Eye On Top Biotech Celgene
 

Keywords :   


4 Reasons To Keep An Eye On Top Biotech Celgene

2015-08-22 16:57:54| Biotech - Topix.net

While Celgene has pulled back with the market, growth prospects for the IBD Big Cap 20 biotech leader remain healthy. Boosted by its buyout of Receptos and investment in Juno Therapeutics, the maker of cancer therapy Revlimid projects revenue growth to more than double to $21 billion in 2020.

Tags: top reasons eye biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
26.06GLE July/Aug. 2024
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06Fox and The Trade Desk extend ad integrations across Fox's portfolio
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
More »